BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Citi
Baxter
Johnson and Johnson
UBS
QuintilesIMS
Chinese Patent Office
Covington
US Army

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: RE39198

« Back to Dashboard

Summary for Patent: RE39198
Title:Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Abstract:Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s): Strupczewski; Joseph T. (Flemington, NJ), Helsley; Grover C. (Rosemont, NJ), Chiang; Yulin (Convent Station, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Glamkowski; Edward J. (Warren, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/712,129
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent RE39198

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-006 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-007 May 6, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent RE39198

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,633,265 United States Patent: 5633265   ( 1 ➤ Subscribe
5,612,342 United States Patent: 5612342   ( 1 ➤ Subscribe
5,580,891 N-[heteroaryl-1-pyrrolidinyl)alkyl]-2-benoxazolinones and related compounds and their therapeutic utility ➤ Subscribe
5,571,814 N-[(4-heteroaryl-1-pyrrolidinyl)alkyl]phthalimides and related compounds and their therapeutic utility ➤ Subscribe
5,578,624 Heteroarylpyrrolidines and their use as antipsychotics and analgesics ➤ Subscribe
5,889,035 1-(Arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-3-(heteroaryl) pyrrolidines and related compounds useful as antipsychotics and analgesics ➤ Subscribe
6,140,345 1-(aryloxyalkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics ➤ Subscribe
5,840,727 (4-heteroaryl)-1-[(2,3-dihydro-1H-isoindol-2-yl) alkyl] piperazines and related compounds and their therapeutic utility ➤ Subscribe
6,420,390 Heteroarylpiperidines and their use as antipsychotics ➤ Subscribe
5,569,653 N-[(4-(heteroaryl)-1-pyrrolidinyl)al kyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE39198

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1110954 ➤ Subscribe
European Patent Office 2311824 ➤ Subscribe
Spain 2076253 ➤ Subscribe
Spain 2206450 ➤ Subscribe
Spain 2283087 ➤ Subscribe
Spain 2354407 ➤ Subscribe
Finland 104072 ➤ Subscribe
Germany 69233796 ➤ Subscribe
Denmark 0402644 ➤ Subscribe
Denmark 0612318 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Merck
Johnson and Johnson
Fish and Richardson
Colorcon
AstraZeneca
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot